ALS awareness. NeuRx Diaphragm Pacing System

December 2011
PN;Dec2011, Vol. 65 Issue 12, p51
Trade Publication
The article reports that the U.S. Food and Drug Administration (FDA) has approved the use of the NeuRx Diaphragm Pacing System (DPS) from Synapse Biomedical Inc. in amyotrophic lateral sclerosis (ALS) treatment in 2011. It says that the marketing approval was due to NeuRx DPS demonstrations that shows the system has the potential to help ALS patients live longer. It adds that NeuRx DPS is a battery-powered external pulse generator (EPG) device that is implanted through laparoscopic surgery.


Related Articles

  • Minimally invasive trans-mediastinal endoscopic approach to insert phrenic stimulation electrodes in the human diaphragm: a preliminary description in cadavers. Assouad, Jalal; Masmoudi, Hicham; Steltzlen, Camille; Grunenwald, Dominique; Delmas, Vincent; Similowski, Thomas // European Journal of Cardio-Thoracic Surgery;Oct2011, Vol. 40 Issue 4, pe142 

    Abstract: Objective: Diaphragm pacing by phrenic nerve (PN) stimulation is currently used for patients with central respiratory paralysis to be weaned from mechanical ventilation. Electrodes are inserted either through bilateral thoracotomy or through four ports laparoscopy. The aim of this...

  • Diaphragm pacing after bilateral implantation of intradiaphragmatic phrenic stimulation electrodes through a transmediastinal endoscopic minimally invasive approach: pilot animal data†. Assouad, Jalal; Masmoudi, Hicham; Gonzalez-Bermejo, Jesus; Morélot-Panzini, Capucine; Diop, Moustapha; Grunenwald, Dominique; Similowski, Thomas // European Journal of Cardio-Thoracic Surgery;Aug2012, Vol. 42 Issue 2, p333 

    OBJECTIVES Phrenic nerve stimulation for diaphragm pacing allows patients with central respiratory paralysis to be weaned from mechanical ventilation. Two procedures are available, either intrathoracic (bilateral thoracotomy) or intradiaphragmatic (four ports laparoscopy). The present...

  • DÄ°YAFRAM PÄ°L UYGULAMALARI VE ÖNERÄ°LER. Şanlı, Aydın // Bulletin of Thoracic Surgery / Toraks Cerrahisi Bülteni;Dec2013, Vol. 4 Issue 4, p280 

    A diaphragmatic pacemaker system is applied to patients with amyotrophic lateral sclerosis associated with chronic respiratory failure, central alveolar hypoventilation and spinal cord injury. There exist two main application principles: directly, or by the stimulation of the phrenic nerve....

  • Idiopathic diaphragmatic weakness.  // BMJ: British Medical Journal (International Edition);2/22/92, Vol. 304 Issue 6825, p492 

    Examines the paralysis of the hemidiaphragm in idiopathic diaphragmatic weakness in Great Britain. Dysfunctions in the phrenic nerve due to malignant infiltration; Symptoms of diaphragm paralysis; Measurement of transdiaphragmatic pressure to assess diaphragm strength.

  • Effects of non-invasive ventilation on objective sleep and nocturnal respiration in patients with amyotrophic lateral sclerosis. Boentert, Matthias; Brenscheidt, Inga; Glatz, Christian; Young, Peter // Journal of Neurology;Sep2015, Vol. 262 Issue 9, p2073 

    In amyotrophic lateral sclerosis (ALS), non-invasive ventilation (NIV) is indicated if sleep-disordered breathing (SDB), daytime hypercapnia, or significant diaphragmatic weakness is present. We investigated both short-term and long-term effects of NIV on objective measures of sleep and...

  • Use of volume-targeted non-invasive bilevel positive airway pressure ventilation in a patient with amyotrophic lateral sclerosis. Diaz-Abad, Montserrat; Brown, John Edward // Jornal Brasileiro de Pneumologia;jul/ago2014, Vol. 40 Issue 4, p443 

    Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which most patients die of respiratory failure. Although volume-targeted non-invasive bilevel positive airway pressure (BPAP) ventilation has been studied in patients with chronic respiratory failure of various...

  • Support services important component of Rilutek launch. Rodgers, Katie // Drug Topics;2/5/96, Vol. 140 Issue 3, p46 

    Reports on the planned launch of Rhone-Poulenc Rhorer's (RPR) Rilutek riluzole drug for amyotrophic lateral sclerosis (ALS). Patient support services; Background information; Implications; Plans and expectations.

  • Understanding Lou Gehrig's disease.  // Patient Care;2/28/1997, Vol. 31 Issue 4, p16 

    Reports on the nationwide program to develop guidelines for the treatment of amyotyhrophic lateral sclerosis (ALS) in the United States. Prevalence of ALS in the country; Contact information for physicians and patients interested to participate in the program.

  • A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis. Bensimon, G.; Lacomblez, L.; Meininger, V. // New England Journal of Medicine;3/3/94, Vol. 330 Issue 9, p585 

    Background: Amyotrophic lateral sclerosis is a progressive motor neuron disease for which there is no adequate treatment. Some research suggests that the excitatory amino acid neurotransmitter glutamate may be involved in the pathogenesis. Methods: To evaluate the efficacy and safety of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics